GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Memphasys Ltd (FRA:IG7) » Definitions » Construction In Progress

Memphasys (FRA:IG7) Construction In Progress : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Memphasys Construction In Progress?


Memphasys Construction In Progress Historical Data

The historical data trend for Memphasys's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Memphasys Construction In Progress Chart

Memphasys Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Memphasys Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Memphasys Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Memphasys (FRA:IG7) Business Description

Traded in Other Exchanges
Address
30 Richmond Road, Homebush, Sydney, NSW, AUS, 2140
Memphasys Ltd is an Australian-based emerging small-cap reproductive biotechnology company. It develops and commercializes novel reproduction and fertility solutions for humans and animals. Its technology includes Hydrogel and other polymer membrane technology development. The company is developing novel medical devices, diagnostics, and media with applications to assisted reproduction technologies, including IVF in humans and artificial insemination in animals.

Memphasys (FRA:IG7) Headlines

No Headlines